1. Generics Bulletin
  2. >>Business

Strides Plans Re-Entry On Injectables

A non-compete agreement with Mylan ends in December

 
• By Vibha Ravi

Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.

ine conveyor for labeling and packaging ampoules in boxes
Strides Moves Back Into Injectables • Source: Shutterstock

Strides Pharma Science Ltd. (earlier known as Strides Pharma Inc.) plans to invest up to $40m for a controlling stake in Indian firm Stelis Biopharma Pvt. Ltd. in a strategic move to gain re-entry into the injectable generics business and capitalize on the latter’s imminent growth prospects.

While Strides currently holds around 43% in Stelis, its stake in the biopharmaceutical company has fluctuated over the years. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Intas Expands Its Plasma Business With A European Acquisition

 
• By Urtė Fultinavičiūtė

Building on its decade-old plasma division in India, Intas and its subsidiary Accord signed an agreement to acquire one of Europe's largest plasma fractionators Prothya Biosolutions.

Richter Sets Launch Timetable for Denosumab and Tocilizumab Biosimilars

 
• By Dean Rudge

Gedeon Richter’s management discussed timelines for two key biosimilars during the firm’s first-half earnings call, while also revealing how the firm’s General Medicines division had suffered setbacks in the three months to June 30.

Viatris Signals Ongoing Strategic Overhaul, Promises Update In Q3

 
• By Dean Rudge

Viatris is conducting a company-wide strategic review to boost long-term competitiveness, targeting cost savings and a shift to complex, high-margin products. CEO Scott Smith says it’s timely after four divestitures. An update is due in the Q3 2025 earnings call in November.

Lupin Couples Up With Sandoz For Global Lucentis Biosimilar Deal

 
• By Urtė Fultinavičiūtė

Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.

More from Generics Bulletin